FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

ALSO NOTED: Shire drug gets second approvable letter; Galapagos acquires ProStrakan sub; FDA asks Allergan for more data; and m

Tools

> The FDA has issued its second approvable letter for Shire's ADHD drug Vyvanse. Report

> Galapagos has acquired ProSkelia, a French subsidiary of ProStrakan in a deal worth up to €45 million. Report 

> Allergan has announced that the FDA has asked for more data on its eye pressure medication Combigan. Report

> The FDA has approved Novartis' Exforge for high blood pressure. Release

> Protiva Biotherapeutics has filed an appeal that seeks to overturn the BC Supreme Court's ruling that would permit Inex Pharmaceuticals Corporation to transfer the Inex-Protiva agreements to Tekmira Corporation without Protiva's consent. Release

And Finally... Drug reps will face a tough year in 2007. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about Novartis   blood pressure   Allergan   Shire Pharmaceuticals   ADHD  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.